A Study to Evaluate the Efficacy and Safety of AD-209

• Status: Not yet recruiting
• Trial end date: 2024-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and safety of AD-209

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Addpharma Inc.

Criteria

Inclusion Criteria:

• Signed informed consent

• Other inclusions applied

Exclusion Criteria:

• orthostatic hypotension with symptom

• Other exclusions applied